Benefits of coronary revascularisation in diabetic and non-diabetic patients with ischaemic cardiomyopathy: Role of myocardial viability

被引:4
作者
Rizzello, Vittoria
Poldermans, Don
Biagini, Elena
Schinkel, Arend F. L.
Boersma, Eric
Elhendy, Abdou
Sozzi, Fabiola B.
Maat, Alexander
Roelandt, Jos R. T. C.
Bax, Jeroen J.
机构
[1] Erasmus MC, Thoraxctr, Dept Cardiol, NL-3015 GD Rotterdam, Netherlands
[2] Univ Cattolica Sacro Cuore, Dept Cardiol, Rome, Italy
[3] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands
关键词
diabetes mellitus; coronary artery disease; myocardial viability; coronary revascularisation; ischaemic cardiomyopathy;
D O I
10.1016/j.ejheart.2005.07.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetes mellitus in patients with coronary artery disease is associated with poor outcome. In this study, the relation between myocardial viability, diabetes, coronary revascularisation and outcome was evaluated. Methods: 129 patients (31 diabetic, 98 non-diabetic) with ischaemic cardiomyopathy underwent dobutamine stress echocardiography to assess myocardial viability. Patients with >= 4 viable segments were defined as viable and patients with < 4 viable segments as nonviable. Left ventricular ejection fraction (LVEF) was assessed before and 9-12 months post-revascularisation. At the same time-points, LV volumes were measured to evaluate LV remodelling. Finally, cardiac events were noted during 5-year follow-up. Results: The extent of viable myocardium was comparable between diabetic and non-diabetic patients. After revascularisation, LVEF increased >= 5% in 44% of diabetic and in 40% of non-diabetic patients. LVEF only improved in patients with viable myocardium. Ongoing LV remodelling occurred in 36% and 35% of diabetic and non-diabetic patients respectively, and was related to non-viability, whereas viability protected against ongoing LV remodelling, both in diabetic and non-diabetic patients. Viability was the only predictor of survival after revascularisation. Conclusions: Diabetic, viable patients with ischaemic LV dysfunction exhibit improvement in LVEF post-revascularisation with prevention of ongoing IV remodelling, similar to non-diabetic patients. Myocardial viability was also the only predictor of long-term outcome. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 34 条
  • [1] THE IMPACT OF DIABETES ON SURVIVAL FOLLOWING MYOCARDIAL-INFARCTION IN MEN VS WOMEN
    ABBOTT, RD
    DONAHUE, RP
    KANNEL, WB
    WILSON, PWF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (23): : 3456 - 3460
  • [2] DOBUTAMINE ECHOCARDIOGRAPHY IN MYOCARDIAL HIBERNATION - OPTIMAL DOSE AND ACCURACY IN PREDICTING RECOVERY OF VENTRICULAR-FUNCTION AFTER CORONARY ANGIOPLASTY
    AFRIDI, I
    KLEIMAN, NS
    RAIZNER, AE
    ZOGHBI, WA
    [J]. CIRCULATION, 1995, 91 (03) : 663 - 670
  • [3] Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis
    Allman, KC
    Shaw, LJ
    Hachamovitch, R
    Udelson, JE
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) : 1151 - 1158
  • [4] AMESE M, 1995, CIRCULATION, V91, P2748
  • [5] MANAGEMENT OF HEART-FAILURE .3. THE ROLE OF REVASCULARIZATION IN THE TREATMENT OF PATIENTS WITH MODERATE OR SEVERE LEFT-VENTRICULAR SYSTOLIC DYSFUNCTION
    BAKER, DW
    JONES, R
    HEDGES, J
    MASSIE, BM
    KONSTAM, MA
    ROSE, EA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19): : 1528 - 1534
  • [6] Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography
    Bax, JJ
    Poldermans, D
    Elhendy, A
    Cornel, JH
    Boersma, E
    Rambaldi, R
    Roelandt, JRTC
    Fioretti, PM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (01) : 163 - 169
  • [7] Cardiovascular critical event pathways for the progression of heart failure -: A report from the ATLAS study
    Cleland, JGF
    Thygesen, K
    Uretsky, BF
    Armstrong, P
    Horowitz, JD
    Massie, B
    Packer, M
    Poole-Wilson, PA
    Rydén, L
    [J]. EUROPEAN HEART JOURNAL, 2001, 22 (17) : 1601 - 1612
  • [8] Impact of diabetes on cardiac structure and function - The strong heart study
    Devereux, RB
    Roman, MJ
    Paranicas, M
    O'Grady, MJ
    Lee, ET
    Welty, TK
    Fabsitz, RR
    Robbins, D
    Rhoades, ER
    Howard, BV
    [J]. CIRCULATION, 2000, 101 (19) : 2271 - 2276
  • [9] Chronic heart failure in the United States - A manifestation of coronary artery disease
    Gheorghiade, M
    Bonow, RO
    [J]. CIRCULATION, 1998, 97 (03) : 282 - 289
  • [10] Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure
    Groenning, BA
    Nilsson, JC
    Sondergaard, L
    Fritz-Hansen, T
    Larsson, HBW
    Hildebrandt, PR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) : 2072 - 2080